Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy

References

• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–567.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Hepatitis C. Fact sheet. [updated 2017 Apr; cited 2017 May 30]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
   Google Scholar
• Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018 Jan;41(1):26–29.
   PubMed Web of Science ®Google Scholar
• Petruzziello A, Marigliano S, Loquercio G, et al. Hepatitis C virus(HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016 Oct 12;11:53.
   PubMed Web of Science ®Google Scholar
• Razavi H, ElKhoury AC, Elbasha E, et al. Chronic Hepatitis C Virus (HCV) disease burden and cost in the United States. Hepatology (Baltimore, Md). 2013;57(6):2164–2170.
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Coppola N, et al. Daclatasvir:thefirst of a new class of drugs targeted against hepatitis C virus NS5A. Curr Med Chem. 2014;21(12):1391–1404.
   PubMed Web of Science ®Google Scholar
• Kondili LA, Gaeta GB, Brunetto MS, et al. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: evaluations from the PITER network. PLoS One. Forthcoming 2017.
   Web of Science ®Google Scholar
• Kondili LA, Vella S; PITER Collaborating Group. PITER: an ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy. Digest Liver Dis. 2015;47:741–743.
   Web of Science ®Google Scholar
• European Medicines Agency. Daklinza authorizations details. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003768/human_med_001792.jsp&mid=WC0b01ac058001d124
   Google Scholar
• EASL recommendations on treatment of hepatitis C. J Hepatol. 2016. DOI:https://doi.org/10.1016/j.jhep.2018.03.026
   Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322–338.
   PubMed Web of Science ®Google Scholar
• Alagoz O, Hsu H, Schaefer AJ, et al. Markov decision processes: atool for sequential decision making under uncertainty. Med Decis Making. 2010;30(4):474–483.
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068–1077.
   PubMed Web of Science ®Google Scholar
• Wright M, Grieve R, Roberts J; UK Mild Hepatitis C Trial Investigators. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess. 2006;10(21):1–113.
   Web of Science ®Google Scholar
• Dienstag JL, Ghany MG, Morgan TR, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011;54(2):396–405.
   PubMed Web of Science ®Google Scholar
• ISTAT. Mortality tables. 2014 [cited 2015 Nov 25]. Available from: http://dati.istat.it/
   Google Scholar
• Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–844.
   PubMed Web of Science ®Google Scholar
• AASLD. Recommendations for testing, managing, and treating hepatitis C. 2016 July.
   Google Scholar
• Ruggeri M, Rolli FR, Coretti S, et al. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy. Value in Health. 2017 Oct;20:A787-A788.
   Web of Science ®Google Scholar
• Munari L, Picciotto A. Recombinant interferon alfa-2b therapy ribavirin for initial treatment of chronic hepatitis C: a random- of chronic hepatitis C in Italy: an economic analysis. FORUM ised trial. Lancet. 2001;358: 958–965. Trends Exp Clin Med 1996; 6: 347-53).
   PubMedGoogle Scholar
• Ministero della Salute Decreto 18 ottobre 2012. Allegato 1. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Serie N.23; Supplemento N.8 del 28 gennaio 2013.
   Google Scholar
• Gruppo multidisciplinare sui farmaci per l’epatite C cronica della Regione Emilia-Romagna. DOCUMENTO DI INDIRIZZO per la definizione delle strategie terapeutiche da applicare sul breve termine per: nuovi antivirali diretti nella terapia dell’epatite C cronica. Aggiornamento settembre 2016.
   Google Scholar
• Ruggeri M, Coretti S, Gasbarrini A, et al. Economic assessment of an anti-HCV screening program in Italy. Value Health. 2013 Sep-Oct;16(6):965–972.
   PubMed Web of Science ®Google Scholar
• Nakamura J, Toyabe SI, Aoyagi Y, et al. Economic impact of extended treatment with peginterferon alpha-2a and ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 2008;15:293–299.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha- 2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. Pharmacoeconomics. 2004;22:257–265.
   PubMed Web of Science ®Google Scholar
• Kondili LA, Gaeta GB, Ieluzzi D, et al. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER cohort study. PLoS One. 2017;12(2):e0172159.
   PubMed Web of Science ®Google Scholar
• Italian Health Economics Association (AIES): proposta di Linee- Guida per la valutazione economica degli interventi sanitari. Italian Health Economics Association. Politiche Sanitarie. 2009;10(2):91–99.
   Google Scholar